Skip to main content
Premium Trial:

Request an Annual Quote

Cyntellect Opens UK Office to Expand European Market

NEW YORK (GenomeWeb News) – US-based cytometry firm Cyntellect today announced the opening of its European operations in Newport, UK.

Cyntellect said that a team of sales, scientific, and service support staff throughout the UK, France, Germany, and the Netherlands will cover all of the European Union.

"With the formation of Cyntellect Europe, we will accelerate the commercialization of our products for applications in cell line development for biopharmaceuticals, drug discovery, and cancer research, including key applications utilizing stem cells," Cyntellect President and CEO Fred Koller said in a statement.

The San Diego-based company also said that it will formally launch two products to the European market at next week's MipTech Conference and Tradeshow in Basel, Switzerland: a cytometer for non-invasive in situ live-cell imaging; and a module to manage stem cell research processes in its flagship cell-processing workstation.

Filed under

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.